Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peyman Hadji

Showing results (31-40 of 171) with videos related to

Pageof 18
Sort By:
Cancer Treatment Reviews|April 10, 2012
Antiresorptive treatment options and bone health in cancer patients-safety profiles and clinical considerationsPeyman Hadji, Matti Aapro, Luis Costa, et al.
Pharmacology & Therapeutics|March 10, 2012
Novel therapies in benign and malignant bone diseasesTilman D Rachner, Peyman Hadji, Lorenz C Hofbauer
Cancer Treatment Reviews|November 4, 2017
Early identification and intervention matters: A comprehensive review of current evidence and recommendations for the monitoring of bone health in patients with cancerThomas Brodowicz, Peyman Hadji, Daniela Niepel, et al.
Archives of Osteoporosis|April 9, 2024
Bone evaluation study-2: update on the epidemiology of osteoporosis in GermanyPeyman Hadji, Elizabeth Esterberg, Dominik Obermüller, et al.
Journal of Bone Oncology|February 25, 2016
Effect of adjuvant bisphosphonates on disease-free survival in early breast cancer: Retrospective analysis results in an unselected single-center cohortPeyman Hadji, Matthias Frank, Andreas Jakob, et al.
International Journal of Clinical Pharmacology and Therapeutics|March 30, 2012
Cost comparison of outpatient treatment with granulocyte colony-stimulating factors (G-CSF) in GermanyPeyman Hadji, Karel Kostev, Detlef Schröder-Bernhardi, et al.
Critical Reviews in Oncology/Hematology|September 18, 2010
Dosing of zoledronic acid throughout the treatment continuum in breast cancerPeyman Hadji, Michael Gnant, Matti Aapro, et al.
The Lancet. Diabetes & Endocrinology|March 25, 2018
Bone health during endocrine therapy for cancerTilman D Rachner, Robert Coleman, Peyman Hadji, et al.
Expert Opinion on Biological Therapy|July 28, 2025
Biosimilars in osteoporosis treatment: focus on denosumabMatti Aapro, Peyman Hadji, Daniele Santini, et al.
International Journal of Clinical Pharmacology and Therapeutics|April 3, 2014
Gender differences in persistency to bisphosphonates in patients with metastatic breast and prostate cancerPeyman Hadji, Jannis Kyvernitakis, Ute Albert, et al.
Pageof 18

Showing results (31-40 of 171) with videos related to

Sort By:
Pageof 18
Cancer Treatment Reviews|April 10, 2012
Antiresorptive treatment options and bone health in cancer patients-safety profiles and clinical considerationsPeyman Hadji, Matti Aapro, Luis Costa, et al.
Pharmacology & Therapeutics|March 10, 2012
Novel therapies in benign and malignant bone diseasesTilman D Rachner, Peyman Hadji, Lorenz C Hofbauer
Cancer Treatment Reviews|November 4, 2017
Early identification and intervention matters: A comprehensive review of current evidence and recommendations for the monitoring of bone health in patients with cancerThomas Brodowicz, Peyman Hadji, Daniela Niepel, et al.
Archives of Osteoporosis|April 9, 2024
Bone evaluation study-2: update on the epidemiology of osteoporosis in GermanyPeyman Hadji, Elizabeth Esterberg, Dominik Obermüller, et al.
Journal of Bone Oncology|February 25, 2016
Effect of adjuvant bisphosphonates on disease-free survival in early breast cancer: Retrospective analysis results in an unselected single-center cohortPeyman Hadji, Matthias Frank, Andreas Jakob, et al.
International Journal of Clinical Pharmacology and Therapeutics|March 30, 2012
Cost comparison of outpatient treatment with granulocyte colony-stimulating factors (G-CSF) in GermanyPeyman Hadji, Karel Kostev, Detlef Schröder-Bernhardi, et al.
Critical Reviews in Oncology/Hematology|September 18, 2010
Dosing of zoledronic acid throughout the treatment continuum in breast cancerPeyman Hadji, Michael Gnant, Matti Aapro, et al.
The Lancet. Diabetes & Endocrinology|March 25, 2018
Bone health during endocrine therapy for cancerTilman D Rachner, Robert Coleman, Peyman Hadji, et al.
Expert Opinion on Biological Therapy|July 28, 2025
Biosimilars in osteoporosis treatment: focus on denosumabMatti Aapro, Peyman Hadji, Daniele Santini, et al.
International Journal of Clinical Pharmacology and Therapeutics|April 3, 2014
Gender differences in persistency to bisphosphonates in patients with metastatic breast and prostate cancerPeyman Hadji, Jannis Kyvernitakis, Ute Albert, et al.
Pageof 18